REGN Investors: Important Deadline Approaching for Securities Claims
If you have invested in REGN Therapeutics Inc. (REGN) securities between February 26, 2015, and November 13, 2019, and have suffered losses as a result, you may be entitled to compensation. The law firm of Johnson Fistel, LLP is investigating potential securities law violations and encourages all affected investors to contact the firm before the Mar. 10, 2025, deadline.
Background
REGN Therapeutics is a biotechnology company that focuses on developing and commercializing innovative therapeutic antibodies for various diseases. However, the company faced a significant setback in 2019 when its lead product, REGN-EB3, failed to meet its primary endpoints in a phase 3 clinical trial for the treatment of Duchenne muscular dystrophy. This news sent REGN’s stock price plummeting, causing significant losses for investors.
Investigation and Deadline
Johnson Fistel, LLP is investigating whether REGN and certain of its officers or directors violated federal securities laws by making false and misleading statements regarding REGN’s business, operational, and financial results. Specifically, the investigation focuses on whether REGN and its executives made misrepresentations about the clinical trial data for REGN-EB3 and the prospects for the drug’s regulatory approval and commercialization.
The firm urges investors who have suffered losses to contact them as soon as possible. The investigation may lead to a securities class action lawsuit against the company, and investors who have suffered losses may be able to recover their damages if the case is successful. The deadline for contacting the firm is Mar. 10, 2025.
Impact on Individual Investors
If you invested in REGN securities during the specified time frame and have suffered losses as a result, you may be entitled to compensation. The amount of compensation depends on the specifics of your case, including the number of shares purchased and the extent of your losses. Contacting the firm as soon as possible increases your chances of being included in any potential securities class action lawsuit and maximizing your potential recovery.
Impact on the World
The failure of REGN-EB3 in clinical trials is a significant setback for the biotechnology industry and the development of potential treatments for Duchenne muscular dystrophy. The industry relies on successful clinical trials to bring new treatments and cures to market, and the failure of a promising drug can have far-reaching consequences. Additionally, the investigation and potential lawsuit against REGN could have implications for other biotech companies and their executives, as it highlights the importance of transparency and accuracy in reporting clinical trial data.
Conclusion
If you invested in REGN Therapeutics securities between February 26, 2015, and November 13, 2019, and have suffered losses, contact Johnson Fistel, LLP as soon as possible. The investigation into potential securities law violations may lead to a securities class action lawsuit, and affected investors may be able to recover their damages if the case is successful. The deadline for contacting the firm is Mar. 10, 2025. The failure of REGN-EB3 in clinical trials is a reminder of the importance of transparency and accuracy in reporting clinical trial data and the potential consequences of misrepresentations.
- Contact Johnson Fistel, LLP if you invested in REGN securities between February 26, 2015, and November 13, 2019, and suffered losses.
- The investigation may lead to a securities class action lawsuit, and affected investors may be able to recover damages if the case is successful.
- The deadline for contacting the firm is Mar. 10, 2025.
- The failure of REGN-EB3 in clinical trials is a reminder of the importance of transparency and accuracy in reporting clinical trial data.
